No Data
No Data
Guotong Pharmaceutical (300966.SZ): The accumulated new borrowing in the year exceeds 20% of the net assets at the end of the previous year.
On July 5th, Gelunhui announced that as of the end of 2023, the company's audited net assets were 1.0237756 billion yuan, and the loan balance was 481.3159 million yuan. As of July 5, 2024, the company's loan balance was 762.3485 million yuan (unaudited), an increase of 281.0326 million yuan from the end of 2023, and the accumulated new borrowing in 2024 accounted for 27.45% of the net assets at the end of 2023.
Jointown Pharmaceutical Group (SZSE: 300966) plans to distribute a cash dividend of 0.16 yuan per share on June 12.
Common Pharm (300966.SZ) announced that the equity distribution plan for 2023 is as follows: 0.16 yuan per 10 shares...
Kyodo Pharmaceutical (300966.SZ): Net profit of 3,5473 million yuan in the first quarter decreased by 11.86% year on year
On April 25, Ge Longhui (300966.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 122 million yuan, up 2.35% year on year; net profit attributable to shareholders of listed companies was 3.5473 million yuan, down 11.86% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 3.4646 million yuan, up 2,911.68% year on year; basic earnings per share were 0.03 yuan.
Pacific Securities: The API industry is in the de-inventory phase or nearing its end, and the 24-year sector is expected to usher in a beta market
The Zhitong Finance App learned that Pacific Securities released a research report saying that in December 2023, production of chemical raw materials by industrial enterprises above the Chinese scale began to resume growth, with a year-on-year increase of 2% and a month-on-month increase of 35%. From January to February 2024, production was 546,000 tons. Although the year-on-year decline was 7.6%, it has already exceeded the same period in 2021 and 2022, continuing the improvement at the end of 2023. As major product patents expire one after another and overseas inventory removal gradually comes to an end, the demand side of the API sector is expected to gradually pick up in 2024, ushering in a beta market. Recommended attention: 1) Continued direction in 2024
Zhitong A Share Sale Restriction and Release List | April 9
According to the Zhitong Finance App, the ban on restricted shares of 7 listed companies was lifted on April 9, with a total market value of about 5.471 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, number of shares unbanned, Huabei Pharmaceutical 600812 issued additional A shares, the original shareholder placed 84.256 million shares before issuance, limited sale and circulation 102 million, Jinyu Medical 603882, the original shareholders placed 3.1237 million additional A shares, the original shareholder placed and listed 3.1237 million Yingqu Technology 002925 share incentives to limit circulation 254,200 CCC Radiation 300962 shares restricted circulation before issuance 1.4
Kyodo Pharmaceutical (300966.SZ): The ban on 43.4691 million shares issued before the initial launch will be lifted on April 9
On April 3, Ge Longhui (300966.SZ) announced an indicative announcement on the listing and circulation of shares issued before the initial public offering. A total of 3 shareholders have lifted the sales restrictions. The number of restricted shares lifted is 43.4691 million shares, accounting for 37.71% of the company's total share capital; the listing and circulation date of the shares that have been lifted is April 9, 2024 (Tuesday).
No Data